Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Thrombocytopenia 6Neoplasms 1Lymphoma 1Liver Diseases 1Jacobs syndrome 1Gastrointestinal Neoplasms 1Chemotherapy-induced Thrombocytopenia 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × avatrombopag × Clear all
NCT06001567 2023-09-14

Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Unknown
30 enrolled
Classical hematologyGastrointestinal

Carcinoma, Hepatocellular, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡